Product Description
Bristol-Myers Squibb was developing avid-100, an intravenous EGFR inhibitor, for the treatment of EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03094169)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AVID100-01 | P2 |
Terminated |
Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer |
2020-11-28 |
55% |